Human recombinant therapeutic proteins

LG1 & LG2 are human recombinant therapeutic proteins which  represent an innovative treatment for Non-Healing Wounds and Peripheral Arterial Disease.

Scientists at MediaPharma have discovered recombinant proteins, named LG1 & LG2, which accelerate wound healing through stimulation of angiogenesis and adhesion via an innovative mechanism.

MediaPharma is sought to develop an application of these products in:

• Diabetic foot ulcers
• Non-healing surgical wounds
• Wounds related to metabolic diseases
• Wounds that repeatedly break down

Administration of these proteins in a murine model of Hind Limb Hischemia (HLI) has shown a significant acceleration of blood flow recovery in the affected limb compared to vehicle treated controls. 

MediaPharma is sought to develop an application of these products in:

• Acute and chronic peripheral arteropathy
• Lower limb ischemia with foot ulcer (diabetic/non-diabetic)